8-K: Amgen Q3 2025 Revenue Jumps 12% on Strong Product Demand

Amgen reported a 12% increase in total revenues to $9.6 billion for the third quarter of 2025, driven by robust volume growth across key products and significant pipeline advancements.

Summary

• Total revenues increased 12% year-over-year to $9.6 billion in the third quarter of 2025.
• Product sales grew 12%, fueled by 14% volume growth, partially offset by a 4% lower net selling price.
• GAAP earnings per share (EPS) rose 14% to $5.93, while non-GAAP EPS increased 1% to $5.64.
• GAAP operating income grew from $2.0 billion to $2.5 billion, with GAAP operating margin increasing 2.5 percentage points to 27.6%.
• Non-GAAP operating income increased from $4.0 billion to $4.3 billion, though non-GAAP operating margin decreased 2.5 percentage points to 47.1%.
• Free cash flow generated was $4.2 billion in Q3 2025, up from $3.3 billion in Q3 2024.
• An Otezla intangible asset impairment charge of $400 million was recorded during the third quarter of 2025.
• Research & Development (R&D) expenses increased 31% due to higher spend in later-stage clinical programs, notably MariTide.
• The company retired $1.6 billion of debt in Q3 2025, bringing the year-to-date total to $6.0 billion, with total debt outstanding at $54.6 billion as of September 30, 2025.
• Sixteen products achieved at least double-digit sales growth, including Repatha (+40%), EVENITY (+36%), IMDELLTRA/IMDYLLTRA (up 33% quarter-over-quarter), TEZSPIRE (+40%), TEPEZZA (+15%), BLINCYTO (+20%), UPLIZNA (+46%), and TAVNEOS (+34%).
• Sales for Enbrel decreased 30% to $580 million, primarily due to lower net selling price from Medicare Part D redesign and increased 340B Program mix.
• Biosimilar competition is expected to drive sales erosion for Prolia and XGEVA for the remainder of 2025.
• MariTide (GLP-1/GIPR) has multiple Phase 3 studies underway for chronic weight management, cardiovascular outcomes, heart failure, and obstructive sleep apnea, with Phase 2 data anticipated in Q4 2025.
• The Phase 3 VESALIUS-CV clinical trial for Repatha met its dual primary endpoints, demonstrating a significant reduction in major adverse cardiovascular events (MACE).
• TEZSPIRE received FDA approval in October for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).

Sentiment

Score: 8

Explanation: The company delivered strong financial results with robust revenue and volume growth, significant free cash flow generation, and positive advancements across a broad and deep pipeline, particularly with MariTide and Repatha. While there are headwinds from biosimilar competition and an impairment charge, the overall performance and future outlook are highly positive.

Positives

• Total revenues increased 12% to $9.6 billion in Q3 2025, demonstrating strong top-line growth.
• Product sales grew 12%, driven by robust 14% volume growth.
• GAAP EPS increased 14% from $5.22 to $5.93, reflecting improved profitability.
• GAAP operating income increased from $2.0 billion to $2.5 billion, and GAAP operating margin improved by 2.5 percentage points to 27.6%.
• Free cash flow surged to $4.2 billion in Q3 2025 from $3.3 billion in Q3 2024, indicating strong liquidity.
• Sixteen products achieved double-digit sales growth, highlighting broad portfolio strength, including Repatha (+40% to $794 million), EVENITY (+36% to $541 million), TEZSPIRE (+40% to $377 million), and UPLIZNA (+46% to $155 million).
• IMDELLTRA/IMDYLLTRA generated $178 million in sales, increasing 33% quarter-over-quarter, showcasing strong uptake for a recently approved product.
• Significant pipeline advancements, including multiple Phase 3 studies for MariTide (GLP-1/GIPR agonist) in obesity, cardiovascular, and sleep apnea indications.
• Repatha's Phase 3 VESALIUS-CV trial met its dual primary endpoints, demonstrating significant reduction in MACE for patients without prior heart attack or stroke, expanding its clinical utility.
• TEZSPIRE received FDA approval in October for chronic rhinosinusitis with nasal polyps (CRSwNP), broadening its market reach.
• The company declared a Q3 2025 dividend of $2.38 per share, a 6% increase from the prior year, signaling confidence in financial performance.

Negatives

• An Otezla intangible asset impairment charge of $400 million was recorded in Q3 2025, impacting GAAP earnings.
• Non-GAAP operating margin decreased 2.5 percentage points to 47.1%, despite higher non-GAAP operating income.
• Enbrel sales decreased 30% year-over-year to $580 million, primarily due to lower net selling price from U.S. Medicare Part D redesign and increased 340B Program mix.
• AMJEVITA/AMGEVITA sales decreased 7% to $154 million due to unfavorable changes to estimated sales deductions.
• KYPROLIS sales decreased 5% to $359 million, driven by lower volume.
• LUMAKRAS/LUMYKRAS sales decreased 2% to $96 million.
• Neulasta sales decreased 16% to $92 million.
• Expected sales erosion for Prolia and XGEVA for the remainder of 2025 due to biosimilar competition, indicating ongoing pressure on established products.

Risks

• Ability to successfully market both new and existing products domestically and internationally.
• Clinical and regulatory developments involving current and future products.
• Sales growth of recently launched products.
• Competition from other products, including biosimilars.
• Difficulties or delays in manufacturing products.
• Global economic conditions, including those resulting from geopolitical relations and government actions.
• Pricing pressure, political and public scrutiny, and reimbursement policies imposed by third-party payers.
• Extensive regulation by domestic and foreign government regulatory authorities.
• Identification of safety, side effects, or manufacturing problems with products after they are on the market.
• Impact of government investigations, litigation, and product liability claims.
• Impact of new tax legislation or exposure to additional tax liabilities.
• Challenges, invalidation, or circumvention of patent protection by competitors.
• Reliance on a few key manufacturing facilities and third parties for manufacturing activities, potentially constraining sales.
• Significant adverse effects on supply, distribution, commercialization, and clinical trials from public health threats.
• Reliance on collaborations with third parties for product development and commercialization.
• Competition for the discovery and development of new products.
• Uncertainty that any particular product candidate or new indication for an existing product will be successful and become commercial.
• Reliance on sole third-party suppliers for certain raw materials, medical devices, and component parts.
• Substantial purchasing leverage of distributors, customers, and payers.
• Discovery of significant problems with a product similar to one of our products that implicate an entire class of products.
• Challenges in collaborating with or acquiring other companies, products, or technology, and integrating their operations.
• Inability to realize strategic benefits, synergies, or opportunities from the Horizon acquisition, or longer/more difficult/costlier integration than expected.
• Compromise of information technology systems due to breakdown, cyberattack, or information security breach.
• Stock price volatility.
• Negative impact from the failure, or perceived failure, of achieving sustainability objectives.
• Negative effects on business and operations from global climate change and related natural disasters.
• Global economic conditions magnifying certain business risks.
• Business performance affecting or limiting the ability of the Board of Directors to declare a dividend or the ability to pay a dividend or repurchase common stock.
• Inability to access capital and credit markets on favorable terms, or at all.

Future Outlook

For the full year 2025, Amgen expects total revenues in the range of $35.8 billion to $36.6 billion. GAAP EPS is projected between $13.76 and $14.60, with a GAAP tax rate of 14.5% to 16.0%. Non-GAAP EPS is anticipated to be in the range of $20.60 to $21.40, with a non-GAAP tax rate of 15.0% to 16.5%. Capital expenditures are forecasted between $2.2 billion and $2.3 billion, and share repurchases are not expected to exceed $500 million.

Management Comments

• "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we’re having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we’re focused on expanding access, advancing innovation, and sustaining long-term growth."

Industry Context

Amgen's strong volume growth across a diverse portfolio, including significant increases for Repatha, EVENITY, and TEZSPIRE, demonstrates its ability to drive demand for innovative medicines, a key differentiator in the competitive biopharmaceutical landscape. The advancement of MariTide into multiple Phase 3 studies positions Amgen as a significant player in the rapidly evolving and highly competitive GLP-1 market, where companies like Eli Lilly (with Zepbound) and Novo Nordisk (with Wegovy) currently dominate. The successful VESALIUS-CV trial for Repatha further solidifies its cardiovascular benefit, a critical area for patient outcomes. However, the continued sales erosion of established products like Enbrel, Prolia, and XGEVA due to biosimilar competition is a common industry challenge, mirroring trends seen by other large pharmaceutical companies facing patent expirations.

Comparison to Industry Standards

• Amgen's 12% year-over-year revenue growth in Q3 2025 is robust, outperforming many established pharmaceutical companies that often face single-digit growth or declines due to patent cliffs and market saturation.
• The significant volume growth of 14% indicates strong market acceptance and demand for Amgen's newer and key growth products, a positive signal compared to industry peers struggling with volume declines.
• The advancement of MariTide into multiple Phase 3 studies positions Amgen as a serious contender in the highly competitive GLP-1 agonist market, currently dominated by products like Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Amgen's differentiated antibody-peptide conjugate approach could offer a unique profile.
• The positive Phase 3 VESALIUS-CV trial results for Repatha, demonstrating a significant reduction in MACE, reinforce its position in cardiovascular risk reduction, comparable to other leading lipid-lowering therapies and expanding its potential patient population beyond those with prior events.
• The sales decline of Enbrel (-30%) and anticipated erosion for Prolia and XGEVA due to biosimilar competition are consistent with broader industry trends where major biologics face significant revenue pressure post-patent expiry, similar to challenges faced by companies like AbbVie with Humira biosimilars.
• The $400 million impairment charge for Otezla, while a GAAP negative, reflects a re-evaluation of asset value, a practice common across the industry when market dynamics or pipeline expectations shift for acquired assets.

Stakeholder Impact

• Shareholders: Positive impact from increased revenues, GAAP EPS, and free cash flow, along with a 6% dividend increase. However, the Otezla impairment and biosimilar erosion on some products could introduce volatility.
• Patients: Continued access to innovative medicines with strong volume growth for key products and advancements in pipeline candidates like MariTide, Repatha, and TEZSPIRE, potentially offering new treatment options.
• Employees: The mention of restructuring and cost savings initiatives in non-GAAP adjustments suggests ongoing operational efficiency efforts, which could impact employee roles, though no specific new details are provided.
• Customers/Payers: Lower net selling prices for some products (e.g., Enbrel) and biosimilar competition could lead to more favorable pricing, while new product launches and expanded indications offer more treatment choices.
• Creditors: Debt retirement of $1.6 billion in the quarter and $6.0 billion year-to-date demonstrates prudent financial management, enhancing creditworthiness.

Next Steps

• Full results from the Repatha VESALIUS-CV trial will be presented at the American Heart Association Scientific Sessions (AHA) on November 8, 2025.
• Submission of Repatha VESALIUS-CV trial results for publication in a peer-reviewed journal.
• Anticipated data readout for MariTide Phase 2 chronic weight management study in Q4 2025.
• Anticipated data readout for MariTide Phase 2 study for the treatment of Type 2 Diabetes in Q4 2025.
• U.S. Food and Drug Administration (FDA) review of UPLIZNA MINT Phase 3 data in generalized myasthenia gravis, with a PDUFA date of December 14, 2025.
• U.S. regulatory review of IMDELLTRA DeLLphi 304 global Phase 3 confirmatory study, with a PDUFA date of December 18, 2025.
• Ongoing global clinical development program for IMDELLTRA across extensive-stage (ES) and limited-stage (LS) small cell lung cancer (SCLC).
• Continued enrollment in various Phase 3 and Phase 1b studies for Xaluritamig in metastatic castrate resistant prostate cancer (mCRPC) and other prostate cancer indications.
• Ongoing Phase 2 and Phase 1/1b/2 studies for AMG 193 in MTAP-null advanced non-small cell lung cancer (NSCLC) and solid tumors.
• Continued enrollment in Phase 3 studies for LUMAKRAS/LUMYKRAS in KRAS G12C-mutated metastatic colorectal cancer and advanced NSCLC.
• Continued enrollment in the Phase 3 PROCLAIM study of Nplate for chemotherapy-induced thrombocytopenia.
• Ongoing comparative clinical studies for biosimilar candidates ABP 206 (nivolumab), ABP 234 (pembrolizumab), and ABP 692 (ocrelizumab).

Key Dates

Recommendation

Amgen's Q3 2025 results demonstrate strong operational execution, with robust 12% revenue growth driven by impressive 14% volume increases across a diverse portfolio of innovative medicines. The significant rise in free cash flow to $4.2 billion underscores financial strength and flexibility. Key pipeline advancements, particularly the multiple Phase 3 studies for MariTide in the high-growth GLP-1 market and the positive cardiovascular outcomes data for Repatha, signal substantial future growth potential. While the $400 million Otezla impairment and ongoing biosimilar erosion for older products like Enbrel present headwinds, these are largely offset by the strength of the growth portfolio and the promising pipeline. The company's ability to deliver strong top-line growth and advance its innovation agenda makes it an attractive investment.

Keywords

Amgen, AMGN, Q3 2025, Earnings, Pharmaceutical, Biotechnology, MariTide, Repatha, Oncology, Inflammation, Rare Disease, Biosimilars, GLP-1, Cardiovascular, Otezla, TEZSPIRE, IMDELLTRA